Salute e Benessere
Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight
Discover the pediatric relapsed/refractory neuroblastoma new treatment @
The pediatric relapsed/refractory neuroblastoma market dynamics are expected to change in the coming years. The pediatric relapsed/refractory neuroblastoma market is primarily driven by the and available for this aggressive and recurrent form of cancer. are catalyzing investment and innovation in this space. are enabling earlier detection and more accurate disease stratification, which supports the adoption of novel therapies. Moreover, such as orphan drug designation and pediatric priority review vouchers are encouraging biopharmaceutical companies to invest in developing therapies for this rare pediatric population.
As potential therapies are being investigated for the treatment of pediatric relapsed/refractory neuroblastoma, it is safe to predict that the treatment space will significantly impact the pediatric relapsed/refractory neuroblastoma market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the pediatric relapsed/refractory neuroblastoma market in the 7MM.
However, several factors may impede the growth of the pediatric relapsed/refractory neuroblastoma market. One major challenge is the , as neuroblastoma is a rare pediatric cancer, and relapsed/refractory cases represent an even smaller subset, making it difficult to conduct large-scale clinical trials and attract substantial investment. Additionally, the contribute to poor response rates and rapid resistance to current treatments. , including stringent pediatric trial requirements and ethical considerations, further complicate drug development. Moreover, there is a , which impedes the design and evaluation of novel therapies.
Moreover, pediatric relapsed/refractory neuroblastoma treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the pediatric relapsed/refractory neuroblastoma market growth may be offset by , , , and a . In addition, the about the disease may also impact the pediatric relapsed/refractory neuroblastoma market growth.
Current treatment options for pediatric patients with relapsed or refractory neuroblastoma include surgery, chemotherapy, radiation therapy, and stem cell transplantation. Several drugs have been approved for this indication, including (developed by USWM and Norgine), (Y-mAbs Therapeutics), and (EUSA Pharma), among others.
IWILFIN is an oral prescription therapy used to reduce the risk of relapse in both adults and children with high-risk neuroblastoma who have shown a response to previous multi-modal treatments. Its active ingredient, eflornithine, irreversibly inhibits the enzyme Ornithine Decarboxylase (ODC)—a key enzyme in polyamine biosynthesis and a transcriptional target of the oncogene MYCN. Polyamines are essential for cellular proliferation and survival, particularly in cancer cells. By blocking polyamine synthesis, eflornithine helps rebalance the LIN28/Let-7 pathway, which regulates cancer stem cells and glycolytic metabolism. This leads to downregulation of MYCN and LIN28B, particularly in MYCN-amplified neuroblastoma, thereby inhibiting tumor growth.
In July 2021 , US WorldMeds entered into an exclusive licensing agreement with Norgine to commercialize eflornithine in Europe . Subsequently, in December 2023 , the FDA approved IWILFIN for use in adult and pediatric patients with high-risk neuroblastoma who had at least a partial response to previous combination therapies, including GD2-targeted immunotherapy. This approval was based on data from an externally controlled trial comparing Study IIIb (treatment arm) with Study ANBL0032 (control). A marketing authorization application for IWILFIN was submitted to the European Medicines Agency (EMA) in January 2025 .
DANYELZA is a GD2-targeting monoclonal antibody indicated for pediatric patients aged one year and older, as well as adults, with relapsed or refractory high-risk neuroblastoma involving the bone or bone marrow. It is used in combination with GM-CSF for patients who have shown at least a stable disease, minor response, or partial response to prior treatments. GD2, a disialoganglioside, is highly expressed on neuroblastoma cells and other neuroectoderm-derived tissues. The antibody naxitamab-gqgk, the active component in DANYELZA, mediates complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) by binding to GD2.
The FDA approved DANYELZA in November 2020 for patients aged one and older with relapsed/refractory neuroblastoma in the bone or bone marrow, based on findings from Study 201 and Study 12-230.
In November 2024 , Y-mAbs Therapeutics announced an exclusive licensing and distribution agreement with Nobelpharma for the development and commercialization of DANYELZA in Japan for high-risk neuroblastoma, with a potential future extension to relapsed osteosarcoma. Under this agreement, Nobelpharma will lead regulatory submissions and oversee marketing, sales, and distribution in Japan upon regulatory approval.
To know more about pediatric relapsed/refractory neuroblastoma treatment options, visit @
The pipeline consists of products such as (Clarity Pharmaceuticals), (afamitresgene autoleucel) (Adaptimmune), (Peel Therapeutics), and others.
is an advanced, next-generation theranostic radiopharmaceutical designed with enhanced specificity and improved in-vivo stability. It targets cancers expressing Somatostatin Receptor 2 (SSTR2) and is being developed for use in diagnosis, staging, and subsequent treatment of these cancers.
Clarity Pharmaceuticals is currently conducting a Phase I/II clinical trial to assess the safety and efficacy of ⁶⁷Cu-SARTATE in pediatric patients with high-risk neuroblastoma. The trial has progressed to Cohort III. Both ⁶⁷Cu-SARTATE and ⁶⁴Cu-SARTATE have received from the U.S. FDA for the treatment and clinical management of neuroblastoma. Additionally, the FDA has granted to ⁶⁷Cu-SARTATE for the treatment of neuroblastoma.
is a nanocarrier-based therapy linked to four small molecules, developed as a cancer treatment. Its active agent is derived from camptothecin, a natural compound from the Chinese Happy Tree, which is believed to have evolved as a plant defense mechanism. Preclinical results have been highly encouraging, demonstrating that PEEL-224 can achieve sustained complete tumor responses in aggressive solid tumors, in some instances lasting over six months.
PEEL-224 is currently being evaluated in a Phase I/II clinical trial for solid tumors, including a neuroblastoma cohort comprising patients aged 1 to 30 years.
The anticipated launch of these emerging therapies are poised to transform the pediatric relapsed/refractory neuroblastoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the pediatric relapsed/refractory neuroblastoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about pediatric relapsed/refractory neuroblastoma marketed and pipeline drugs @
Neuroblastoma is a type of cancer that arises from immature nerve cells, known as neuroblasts, typically in infants and young children, most often before the age of five. In many cases, it begins during infancy and can even be detected within the first month of life. While it commonly originates in the adrenal glands, it can also form in other areas such as the neck, chest, or along the spine. This cancer is considered aggressive because it frequently spreads to other parts of the body by the time it is diagnosed.
Symptoms can vary but may include a noticeable lump at the tumor site, bone pain, gastrointestinal issues like diarrhea, and neurological problems. The underlying cause of neuroblastoma is usually unknown, although in rare cases, it may result from inherited genetic mutations, such as those in the ALK or PHOX2B genes.
Advances in research have significantly improved survival rates, but challenges remain. About 10% to 15% of children with high-risk neuroblastoma do not respond to initial therapy, and approximately 40% to 50% experience a return of the disease after treatment.
Diagnosis involves a thorough evaluation, including physical examination, blood tests, imaging techniques such as MRI and CT scans, and confirmation via biopsy. Two main staging systems are used to classify the disease: the International Neuroblastoma Risk Group Staging System (INRGSS), which is based on imaging before treatment (L1, L2, M, MS), and the International Neuroblastoma Staging System (INSS), which uses surgical findings (Stages I–IV, 4S). Risk assessment under the INRG framework incorporates both clinical and genetic factors, such as MYCN gene amplification, chromosome 11q status, and tumor cell ploidy, to categorize tumors into very low-, low-, intermediate-, or high-risk groups.
The pediatric relapsed/refractory neuroblastoma epidemiology section provides insights into the historical and current pediatric relapsed/refractory neuroblastoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The pediatric relapsed/refractory neuroblastoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Download the report to understand which factors are driving pediatric relapsed/refractory neuroblastoma therapeutics market trends @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pediatric neuroblastoma companies including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroblastoma companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key neuroblastoma companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pediatric neuroblastoma companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/pediatric-relapsedrefractory-neuroblastoma-market-is-on-an-upward-trend-driven-by-innovation-and-unmet-need--delveinsight-302529861.html